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Abstract
Background: Martorell hypertensive ischemic leg ulcer (Martorell ulcer) is characterized by distinct alterations in the
arteriolar wall of subcutaneous vessels, leading to progressive narrowing of the vascular lumen and increase of
vascular resistance. These changes are similar to the alterations observed in pulmonary arterioles in patients with
chronic pulmonary hypertension (PH). This study was aimed to assess an association between the two disorders.
Methods: In this case–control study, 14 patients with Martorell ulcer were clinically assessed for the presence of
pulmonary hypertension using transthoracic Doppler echocardiography. Data from patients were compared to 28
matched hypertensive controls.
Results: Systolic pulmonary arterial pressure (sPAP) in patients with Martorell ulcer was significantly higher than in
the control group (33.8 ± 16.9 vs 25.3 ± 6.5 mmHg, p = 0.023); the prevalence of pulmonary hypertension was 31%
(5/14) in patients and 7% (2/28) in controls (p = 0.031). No differences were seen in left heart size and function
between patients and controls.
Conclusion: This study provides first evidence that subcutaneous arteriolosclerosis, the hallmark of Martorell ulcer,
is associated with PH. These findings suggest that patients with Martorell leg ulcer might be at significant risk to
develop elevated pulmonary arterial pressure. Patients with leg ulcers who present with dyspnea should be
evaluated by echocardiography for the presence of pulmonary hypertension.
Keywords: Pulmonary hypertension, Echocardiography, Martorell ulcer
Background
Martorell hypertensive ischemic leg ulcer (HYTILU,
Martorell ulcer) and pulmonary hypertension (PH) are
distinct clinical entities that share common pathogenic
features. Of particular interest are similar morphologic
changes of arterioles that cause elevated vascular resist-
ance. These similarities suggest a possible association
between the two disorders.
In 1945, Fernandes Martorell described 4 cases of
patients with ischemic leg ulcers [1] that occurred in the
absence of peripheral arterial or venous disease; histo-
logical analysis of these ulcers revealed hypertensive
changes of subcutaneous arterioles (i.e. hypertrophy and
stenosis), which resulted in the descriptive term “hyper-
tensive ischemic leg ulcer” [2,3]. Martorell ulcer is an
entity defined by ischemic subcutaneous arteriolosclero-
sis of the leg in hypertensive subjects. Martorell ulcer is
a rare cause for leg ulcers and is found in approximately
5% of cases. Diagnosis is based on clinical presentation,
patient history and deep skin biopsy. Histology reveals
hypertrophy of the smooth muscle cell layer of the
vessel’s media resulting in an increased thickness of the
arteriolar wall to the cost of a narrow lumen (Figure 1a/b).
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Systemic arterial hypertension is present in all cases, type
2 diabetes is observed in approximately 60% [4-6].
Histopathology of pulmonary vasculature in patients
with P(A)H are comparable to those of Martorell ulcer.
PAH is a pre-capillary disorder of the small pulmonary
arteries and arterioles, characterized by extensive vaso-
constriction, in situ thrombosis and vascular remodel-
ling. Cellular changes defining the vascular remodelling
include intimal fibrosis, medial and adventitial hyperpla-
sia and a pro-proliferative, apoptosis-resistant phenotype
of vascular cells. These alterations progressively narrow
the arteriolar lumen and, thus, increase the pulmonary
vascular resistance (PVR) leading to an increase of the
right ventricular afterload and, ultimately, cardiac failure
[7-10]. Of interest, these histopathological changes are
not restricted to PAH but can be observed in several
other forms of PH [11].
On the other hand, Martorell ulcers have been found
to develop secondary to limited skin perfusion pressures
resulting from an increase of vascular resistance in small
cutaneous vessels. It has also been suggested that this in-
crease of vascular resistance affects the vessel relaxation
that usually follows distal to an arterial narrowing, which
might further decrease tissue perfusion [12].
The striking histopathological and pathophysiologic
similarities between Martorell ulcer and PAH as well as
Figure 1 a) Overview of necrotic skin area at the border of a Martorell hypertensive ischemic leg ulcer, containing a group of two
sclerotic arterioles; 1b) Higher magnification of Figure 1a; Group of two sclerotic arterioles, one with a thickened wall to the cost of a narrow
lumen and one showing medial calcification.
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chronic PH due to other conditions prompted this
case–control study. The aim was to analyse a potential
association between Martorell ulcer and the develop-
ment of PH.
Methods
Patients
From May 1999 to April 2011, 46 patients with Martorell
ulcer were diagnosed at the Department of Dermatology,
University Hospital of Zurich [4]. After reviewing the
cases, a total of 15 patients were identified for further
diagnostic workup according to the study design
(Figure 2). Patient history was checked for i) the
presence of chronic obstructive or restrictive pul-
monary disease, ii) chronic thromboembolic pulmon-
ary hypertension and iii) concomitant diagnosis of
systemic disorders that have been associated with the
development of pulmonary hypertension due to un-
clear multifactorial mechanisms (e.g. sarcoidosis,
neurofibromatosis, tumoral obstruction, etc.) [13].
Patients characteristics are shown in Table 1. For
each case, 2 controls were matched to gender, age at
time of echocardiography (± 2 years), presence of
hypertension, current smoking and presence or ab-
sence of diabetes mellitus. Data were retrieved from
the electronical data pool of the hospital and included
in-patients from all hospital departments. Echocardio-
graphic workup was performed at the Department of
Cardiology, University Hospital of Zurich, Switzerland
(12 of 14 patients) as well as in 2 other hospitals (2 of
14 patients).
Study design
The study was conducted at a tertiary care hospital (Uni-
versity Hospital of Zurich, Switzerland) and was
approved by the ethics committee of the medical faculty
of the University of Zurich. The study was designed as
case–control study to investigate a potential correlation
between the presence of Martorell ulcer and pulmonary
hypertension (PH).
Echocardiography
All patients underwent a complete transthoracic echo-
cardiographic study. Pulmonary arterial pressure (sys-
tolic pulmonary arterial pressure, sPAP) was estimated
in a non-invasive manner by measuring the maximal vel-
ocity of the tricuspid regurgitation jet and calculating
the maximal instantaneous systolic pressure difference
between the right ventricle and the right atrium [14].
Pulmonary hypertension was defined according to the
Dana Point criteria as sPAP >36 mmHg, i.e. a tricuspid
jet velocity of >2.8 m/s corresponding to an RV/RA gra-
dient of >31 mmHg and adding a right atrial pressure
estimate of 5 mmHg [15]. Diastolic dysfunction was esti-
mated by measurement of left atrial diameter [reference
< 4.0 cm] and right atrial diameter (as assessed by short
[< 4.1 cm] and long axis [< 5.0 cm]) as well as analysis
of the E/A-ratio, defined as flow velocity of passive fill-
ing of the left ventricle divided by flow velocity of active
filling due to atrial contraction [> 1].
Statistics
All data are shown as mean± standard deviation (confi-
dence interval of 95%). Data were checked for normality
by using the Kolmogorov-Smirnov test. Statistical com-
parison between patients and controls were assessed
with the use of the student’s t-test. A p-value <0.05 wasFigure 2 Study design.
Table 1 Characteristics of patients and controls
Numbers investigated, n 14 28
Age at time of echocardiography – yr. (± SD) 77 (± 5) 77 (± 5)
Male sex – no. (%) 6 (42%) 12 (43%)
Present hypertension – no. (%) 14 (100%) 28 (100%)
Present diabetes – no. (%) 5 (37%) 10 (36%)
Smoker status
Current smoker – no. (%) 2 (14%) 4 (14%)
Former smoker – no. (%) 3 (22%) 6 (21%)
Never smoked – no. (%) 9 (64%) 18 (64%)
Oral anticoagulation (phenprocoumon) – no. (%) 7 (50%) 8 (28%)
Antinuclear antibodies (ANA)
Titer≤ 1:160 – no. (%) 12 (86%) n / a
Titer> 1:160 – no. (%) 2 (14%) n / a
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considered to be statistically significant. Spearman’s test
was used for correlation analysis.
Results
Characteristics of patients and controls
46 patients with Martorell ulcer were retrieved from a
retrospective data base. Twentytwo files concerned sub-
jects who were already deceased, leaving a total of 24 eli-
gible patients. One patient was excluded because of
retrospectively revised diagnosis of peripheral arterial
disease instead of Martorell ulcer. Eight patients refused
to participate at the study. Fifteen patients were further
evaluated for the presence of PH by echocardiography.
One patient was excluded after analysis because systolic
RV/RA gradient could not be measured due to absence
of tricuspid regurgitation.
Patient data from 14 patients with Martorell ulcer
were compared to data of the control group; details of
patients’ characteristics are provided in Table 2. Briefly,
6 of 14 patients (42%) were male, the mean age was
77 years (range 70–89 years). Hypertension was present
in all patients with Martorell ulcer (100%), type 2 dia-
betes mellitus was found in 5 of 14 patients (37%). 2
patients (14%) were still active smokers whereas 3 (22%)
had stopped smoking (former smokers), 9 (64%) had
never smoked. Creatinine levels and estimated glomeru-
lar filtration rate (GFR) as calculated according to
MDRD (modified diet in renal disease formula [16])
were normal in 6 of 14 patients (42%) and in 12 of 28
controls (43%) [reference range 70 – 110 μmol/l]. Renal
function was moderately reduced in 6 of 14 patients
(CKD stage 3 in 42% patients) and in 14 of 28 controls
(50%). 2 of 14 patients (16%) and 2 of 28 controls (7%)
showed severe (CKD stage 4) reduction in renal func-
tion. Creatinine levels at time of echocardiography
(109 ± 51 vs. 104 ± 42 μmol/l) and GFR according to
MDRD (64 ± 37 vs. 59 ± 19 ml/min) did not reveal
significant differences between patients and controls.
Oral anticoagulation was established in 8 of 14 patients
(50%) and in 8 of 28 controls (28%). Levels of antinuc-
lear antibodies (ANA) were negative in 6 of 14 patients;
elevations above 1:160, which is used as cut-off at the
University Hospital Zurich, were observed in 2 patients
(14%) without clinical signs of a systemic autoimmune
disease. Since Martorell ulcer was diagnosed by tissue
biopsy, no evidence for coumarin-induced skin necrosis
or autoimmune disorders associated with the develop-
ment of ulcerating lesions has been found.
Body mass index (BMI, defined as body weight in kilo-
grams divided per height in square meters) of patients
with Martorell ulcer was significantly higher than in the
control group (29.5 ±7.0 vs 25.8 ± 4.0 kg/m2).
The RV/RA gradient is significantly elevated in patients
with martorell ulcer
As shown in Figure 3a, the RV/RA gradient systolic pul-
monary arterial pressure (sPAP) in patients with Martor-
ell ulcer (33.8 ± 16.9 mmHg) was significantly higher
than the pressure measured in the control group
(25.3 ± 6.5 mmHg, p = 0.023). The absolute difference be-
tween the means of the gradients of cases and controls
was 8.5 mmHg. This difference was independent of left
heart function, since all 14 patients showed a normal left
ventricular ejection fraction (LVEF ≥ 50%, 62%± 3). On
the other hand, in 4 of 28 controls the LVEF was found
to be impaired (58%± 12); the difference observed be-
tween left ventricular function of patients and controls
however was not significant. Dilatation of the left atrium
(end-systolic-diameter (ESD)> 4 cm) is considered to be
an important surrogate marker of diastolic dysfunction,
which, in turn, might lead to pulmonary hypertension.
Left atrial ESD exceeding 4.0 cm was found in 10 of 14
patients (71%) and in 16 of 28 controls (57%). The differ-
ence in left atrial ESD between patients (4.47 cm±1.05)
Table 2 Comparison between patients and controls
Δ P systolic RV / RA – mmHg (± SD) 33.8 (± 16.9) 25.3 (± 6.5) p = 0.023
Pulmonary hypertension (sPAP> 36 mmHg) – no. (%) 5 (36%) 2 (7%) p = 0.031
Left ventricular ejection fraction – % (± SD) 62 (± 3) 58 (± 12) ns
Left atrial diameter (ESD)– cm (± SD) 4.47 (± 1.05) 4.35 (± 0.80) ns
Right atrial diameter (ESD) long axis – cm (± SD) 5.20 (± 1.04) 5.08 (± 0.83) ns
Right atrial diameter (ESD) short axis – cm (± SD) 3.84 (± 0.80) 3.72 (± 0.75) ns
E / A ratio – mean (± SD) * 0.90 (± 0.23) 0.91 (± 0.37) ns
Significant valvular heart disease – no. (%) † 3 (21%) 5 (17%) ns
Creatinine level – μmol/l (± SD) 109 (± 51) 104 (± 42) ns
GFR estimated by MDRD – ml/min (± SD) 64 (± 37) 59 (± 19) ns
Body Mass Index (BMI) – kg/m2 (± SD) 29.57 (± 7.08) 25.84 (± 5.07) p = 0.036
* E / A ratio could not be assessed due to atrial fibrillation in 5 of 14 patients and in 8 of 28 controls.
† Mitral insufficiency in 1 of 14 patients and 3 of 28 controls; severe aortic stenosis in 2/14 and 2/28, respectively.
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and controls (4.35 cm± 0.80) is illustrated in Figure 3b
and was not statistically significant. Measurement of
right atrial diameter assessed by long and short axis did
not differ between patients and controls. Similarly, no
significant differences were found in the E/A-ratio be-
tween the patient group and the control group.
The prevalence of pulmonary hypertension in patients
with martorell ulcer is significantly higher than in controls
When pulmonary hypertension was defined as sPAP
>36 mmHg or as RV/RA gradient of >31 mmHg, re-
spectively [15], the prevalence of pulmonary hyperten-
sion in patients with Martorell ulcer was 5 out of the 14
cases (36%). This figure was significantly higher than in
the control group, in which only 2 out of 28 cases (7%)
had an elevated RV/RA gradient (p = 0.031).
The BMI in patients with martorell ulcer was higher than
in controls
Of interest, the absolute difference of the BMI between
patients and controls was 3.7 kg/m2; this difference did
reach statistical significance (Figure 3c, p= 0.036). Figure 3d
shows the prevalence of pulmonary hypertension in
patients and controls with or without elevated BMI. 30% of
patients with a BMI> 25 were found to have pulmonary
hypertension as compared to 6.25% of obese controls. On
the other hand, 50% of Martorell patients with a BMI< 25
were detected to have an elevated sPAP as compared to
Figure 3 Differences between patients and controls. a) The RV/RA gradient is significantly higher in patients as compared to matched
controls (p = 0.023); b) the end systolic diameter (ESD) of the left atrium is not significantly different between patients and controls; c) the BMI is
higher in patients than in controls (p = 0.036); d) prevalence of PH in patients and controls with elevated BMI (cut-off 25 kg/m2). Data in a - c are
plotted as median including upper and lower whisker.
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8.3% of non-obese controls. For severity of pulmonary
hypertension, no association between BMI and sPAP was
found in patients or in the collective population of investi-
gated patients and controls (data not shown).
Discussion
In the present study, we investigated the prevalence of
PH in subjects with Martorell ulcer and found that the
sPAP as assessed by echocardiography is significantly
elevated in patients as compared to matched hyperten-
sive controls.
Martorell ulcer is caused by hypertensive changes in
subcutaneous skin arterioles leading to reduced tissue
perfusion; Martorell ulcer is, though underdiagnosed, an
uncommon cause for leg ulcers [4]. PAH is another or-
phan disease defined by increased pulmonary arterial
pressure due to remodelling of small pulmonary arteries.
The list of associated conditions and risk factors predis-
posing for the development of PAH however has been
growing constantly [13]. Moreover, when all conditions
are considered that result in elevation of pulmonary
pressure, PH is of emerging clinical relevance.
Histopathological changes observed in the peripheral
arterial vessels within a Martorell ulcer include stenotic
arteriosclerosis with calcification and hypertrophy of the
vessels media, resulting in an increase of the wall to
lumen ratio [Figure 1]. Of interest, similar changes are
seen in the remodeling of arteries described in the pul-
monary vasculature of patients with several forms of
chronic PH including hypertrophy and hyperplasia of
smooth muscle fibers in the media of muscular arteries
resulting in an increase of the cross sectional area
[11,17].
In this case–control study, we found that patients with
Martorell ulcer have significantly higher levels of sPAP
compared to a matched control group. This difference
has been assessed in a non-invasive manner by the use
of transthoracic echocardiography. This method has
been challenged by a recent study and was found to be
inaccurate for diagnosing PH [18]; however, Doppler
echocardiography is a validated and largely utilized mo-
dality to assess right ventricular function and is the cur-
rently established approach to screen patients for
elevated pressure within the pulmonary circulation [19].
Of course, the method is limited for several reasons and
does not permit direct conclusions on the type of PH.
Right heart catheterization to confirm the diagnosis and
evaluate the severity of PH was not considered as feas-
ible approach within this distinct study population; study
design and ethical proposal thus were based on echocar-
diographic assessment. Patients and controls did not
show significant differences when compared for left ven-
tricular function, volume of left and right atrium, E/A
ratio or the presence of significant valvular heart disease.
However, the difference in BMI between patients and
controls reached statistical significance. Together with
the presence of other risk factors for a metabolic syn-
drome, such as age, systemic arterial hypertension and
diabetes mellitus, these data suggest that diastolic heart
failure is of major importance in the development of an
elevated pulmonary arterial pressure – in both patients
with Martorell leg ulcer and hypertensive controls. Of
interest, however, more Martorell patients with a normal
BMI developed pulmonary hypertension than obese
patients. Whether the significantly increased prevalence
of pulmonary hypertension in patients with Martorell
leg ulcer might additionally be caused by other, pre-
capillary factors remains, mainly due to the lack of
invasive hemodynamic data and the absence of histo-
pathological evidence for remodelling of pulmonary ar-
terioles, hypothetically.
The main finding of this study, i.e. that the prevalence
of an elevated pulmonary arterial pressure in patients
with Martorell leg ulcer was significantly higher than in
the control group, suggest that patients with Martorell
ulcer appear to have an increased risk to develop PH,
most probably due to diastolic heart failure, which can
be prominent in patients with Martorell leg ulcer due to
longstanding arterial hypertension. Other studies will
have to investigate whether the presence of Martorell leg
ulcer might additionally predispose for pre-capillary PH
as it was shown similarly for hyperthyroidism [20], con-
comitant HIV infection [21] or smoking [22].
Our data further imply that hypertensive patients with
leg ulcers who present with signs of right heart failure in-
cluding dyspnea, peripheral edema, hypoxemia and
reduced exercise capacity should undergo prompt echo-
cardiographic evaluation to exclude or confirm the pres-
ence of an elevated sPAP. Since adequate treatment of
hypertension does not prevent Martorell ulcer [4], it
seems unlikely that the development of PH can be avoided
by the control of systemic blood pressure. On the other
hand, it remains unclear whether the specific therapy
with vasodilatating agents (e. g. phosphodiesterase-5 in-
hibitors or endothelin receptor antagonists) might im-
prove tissue perfusion and, thus, would enhance the
wound healing of Martorell ulcer. However, patients with
Martorell ulcer and concomitant PH could benefit from
early diagnosis and onset of an adequate therapy.
Our study is limited, as mentioned above, by the fact
that pulmonary arterial pressures were assessed non-
invasively by echocardiography and not by right heart
catheterization; moreover, the study lacks supporting
biomarker data, and, finally, the case number is low,
which is due to the fact that Martorell ulcer is a rare dis-
ease. Since this study was designed as observational and
not as interventional study, the low case numbers should
not severely affect our conclusions.
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Conclusion
Taken together, this is to our knowledge the first report
showing a potential association between the develop-
ment of PH and Martorell ulcer. Patients with Martorell
ulcer might be at significant risk to develop PH. Our
data emphasize that hypertensive patients with leg ulcers
should promptly be screened for the presence of an ele-
vated pulmonary arterial pressure when presenting with
dyspnea, hypoxemia or reduced exercise capacity.
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